

March 11, 2019



# Corbus Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference

*- Presentation with live audio webcast on Tuesday, March 19, 2019 at 2:10 p.m. ET-*

Norwood, MA, March 11, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company with the industry's leading pipeline focused on treating inflammatory and fibrotic diseases through the endocannabinoid system pathways, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at Oppenheimer's 29<sup>th</sup> Annual Healthcare Conference on Tuesday, March 19 at 2:10 p.m. ET in New York, NY.

A live audio [webcast](#) of the Company's presentation at Oppenheimer's 29th Annual Healthcare Conference will be accessible on the [Events](#) page of the [Investors](#) section of Corbus website, [www.corbuspharma.com](http://www.corbuspharma.com), and will be archived on the Company's website for 90 days following the event.

## About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of endocannabinoid system-targeting synthetic drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Corbus is also developing a pipeline of drug candidates from more than 600 novel compounds targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist designed to eliminate blood-brain barrier penetration and subsequent brain CB1 receptor occupancy that mediates the neuropsychiatric adverse events associated with first-generation CB1 inverse agonists. Potential indications for CRB-4001 include NASH, primary biliary cholangitis, idiopathic pulmonary fibrosis, radiation-induced pulmonary fibrosis, myocardial fibrosis after myocardial infarction and acute interstitial nephritis, among others. Corbus plans to enter a Phase 1 study of CRB-4001 in 2019, intended to be followed by a National Institutes of Health (NIH)-funded proof-of-concept Phase 2 study.

For more information, please visit [www.CorbusPharma.com](http://www.CorbusPharma.com) and connect with the Company

on [Twitter](#), [LinkedIn](#), and [Facebook](#).

## **Forward-Looking Statements**

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

## **Corbus Investor Contacts:**

### **Institutional Investor Inquiries**

Ted Jenkins, Senior Director, Investor Relations and Communications  
Corbus Pharmaceuticals, Inc.  
Phone: +1 (617) 415-7745  
Email: [ir@corbuspharma.com](mailto:ir@corbuspharma.com)

### **All Other Investor Inquiries**

Jenene Thomas  
Jenene Thomas Communications, LLC  
Phone: +1 (833) 475-8247  
Email: [crbp@jtcir.com](mailto:crbp@jtcir.com)

### **Media Contact**

Lindsey Smith, Associate Director, Investor Relations and Corporate Communications  
Corbus Pharmaceuticals, Inc.  
Email: [mediainfo@corbuspharma.com](mailto:mediainfo@corbuspharma.com)



Source: Corbus Pharmaceuticals Holdings, Inc.